trending Market Intelligence /marketintelligence/en/news-insights/trending/9u2HmK2Euz1EAyeW-LTFYQ2 content esgSubNav
In This List

Merck's Keytruda fails as 2nd line treatment for gastric cancer in phase 3 trial

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Merck's Keytruda fails as 2nd line treatment for gastric cancer in phase 3 trial

Merck & Co. Inc.'s phase 3 trial of Keytruda as a second-line treatment for a certain gastric cancer failed to meet its main goal of overall survival.

The KEYNOTE-061 study was evaluating Keytruda as a second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1.

In addition, progression free survival in the PD-L1 positive population did not show statistical significance.

Merck will continue to evaluate Keytruda as a monotherapy or in combination with chemotherapy in another phase 3 trial, KEYNOTE-062, as first-line treatment for patients with PD-L1 positive advanced gastric or gastroesophageal junction cancer.

In September, the U.S. Food and Drug Administration approved Keytruda as a third-line treatment for previously treated patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumors express PD-L1.